Key facts
- This page summarizes Jason Ehrlich's Form 4 filing for Kodiak Sciences Inc. (KOD).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 16 Jun 2023, 20:27.
Jason Ehrlich - 14 Jun 2023 Form 4 Insider Report for Kodiak Sciences Inc. (KOD)
- Reporting relationship
- Chief Medical Officer and Chief Development Officer
- Issuer ticker
- KOD
- Reported as of
- 14 Jun 2023
- Net transaction value
- -$31,505
- SEC form
- 4
- Accepted by SEC
- 16 Jun 2023, 20:27:04 UTC
- Prior SEC filing
- 13 Jun 2023
- Next SEC filing
- 27 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jason Ehrlich filed Form 4 for Kodiak Sciences Inc. (KOD) on 16 Jun 2023.
Change
- Previous filing in this sequence was filed on 13 Jun 2023.
- Current net transaction value: -$31,505.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KOD
transaction
Common Stock
Sale
- Transaction value
- $10,663
- Shares
- -1,132
- Change %
- -1.9%
- Price
- $9.42
- Shares after
- 58,688
- Date
- 14 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
KOD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +5,494
- Change %
- +9.4%
- Price
- Shares after
- 64,182
- Date
- 15 Jun 2023
- Ownership
- Direct
- Footnotes
- F2
KOD
transaction
Common Stock
Sale
- Transaction value
- $20,841
- Shares
- -2,258
- Change %
- -3.5%
- Price
- $9.23
- Shares after
- 61,924
- Date
- 16 Jun 2023
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KOD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -3,619
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 3,619
- Date
- 15 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,619
- Exercise price
- Footnotes
- F2, F4
KOD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,875
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 3,750
- Date
- 15 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,875
- Exercise price
- Footnotes
- F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units ("RSU") on June 11, 2023. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
Footnote F2
Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock.
Footnote F3
The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSUs on June 15, 2023. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
Footnote F4
One-fourth (1/4th) of the RSUs vest on each of the first four anniversaries of June 15, 2020, subject to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.
Footnote F5
One-fourth (1/4th) of the RSUs vest on each of the first four anniversaries of June 15, 2021, subject to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.
SEC remarks
Chief Medical Officer and Chief Development Officer